• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Dr Joseph Fuhr: The Immediate Economic Impact of Biosimilars May be Limited

Video

Joseph P. Fuhr, Jr, PhD, professor emeritus, Widener University, sees a limited economic impact for biosimilars given current patent disputes.

Transcript (slightly modified)

What will be the immediate economic impact of biosimilars?

In the next few years I see very little economic impact (of biosimilars). There are currently 2 in the market and they are both risk launches. All are involved in various patent disputes and the Supreme Court is looking at 2 issues concerning the 180-day notice of entry and the other concerning whether the patent dance is mandatory.

As with any new industry, [biosimilars] will take time to develop and so their economic impact will be minimal.

Related Videos
Lakesha Farmer, PharmD
Lakesha Farmer from Cencora
Jeffrey Casberg, RPh, MS.
Adam Colborn, JD.
Legal scale weighs profit as greater than medical treatment
Ha Kung Wong, JD.
Ha Kung Wong, JD
Cencora's Corey Ford
Related Content
© 2024 MJH Life Sciences

All rights reserved.